Literature DB >> 1826763

Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant.

R S Struthers1, W W Vale, C Arias, P E Sawchenko, M R Montminy.   

Abstract

Most of the transcriptional effects of cyclic AMP are mediated by the cAMP response element binding protein (CREB). After activation of cAMP-dependent protein kinase A, the catalytic subunits of this enzyme apparently mediate the phosphorylation and activation of CREB. As cAMP serves as a mitogenic signal for anterior pituitary somatotrophic cells, we investigated whether CREB similarly regulates proliferation of these cells. We prepared transgenic mice expressing a transcriptionally inactive mutant of CREB (CREBM1), which cannot be phosphorylated, in cells of the anterior pituitary. If CREB activity is required for proliferation, the overexpressed mutant protein would effectively compete with wild-type CREB activity and thereby block the response to cAMP. As predicted, the CREBM1 transgenic mice exhibited a dwarf phenotype with atrophied pituitary glands markedly deficient in somatotroph but not other cell types. We conclude that transcriptional activation of CREB is necessary for the normal development of a highly restricted cell type, and that environmental cues, possibly provided by the hypothalamic growth hormone-releasing factor, are necessary for population of the pituitary by somatotrophic cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826763     DOI: 10.1038/350622a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  57 in total

1.  Distinct cAMP response element-binding protein (CREB) domains stimulate different steps in a concerted mechanism of transcription activation.

Authors:  J Kim; J Lu; P G Quinn
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

2.  CtBP1 interacts with Ikaros and modulates pituitary tumor cell survival and response to hypoxia.

Authors:  Katie Dorman; Zhongyi Shen; Caimei Yang; Shereen Ezzat; Sylvia L Asa
Journal:  Mol Endocrinol       Date:  2012-02-02

Review 3.  Mitogenic pathways regulated by G protein oncogenes.

Authors:  S K Gupta; C Gallego; G L Johnson
Journal:  Mol Biol Cell       Date:  1992-01       Impact factor: 4.138

4.  CaMKII and CaMKIV mediate distinct prosurvival signaling pathways in response to depolarization in neurons.

Authors:  Jinwoong Bok; Qiong Wang; Jie Huang; Steven H Green
Journal:  Mol Cell Neurosci       Date:  2007-06-27       Impact factor: 4.314

Review 5.  Genetic dissection of neural circuits and behavior in Mus musculus.

Authors:  Robbert Havekes; Ted Abel
Journal:  Adv Genet       Date:  2009       Impact factor: 1.944

6.  Characterization of a CREB gain-of-function mutant with constitutive transcriptional activity in vivo.

Authors:  K Du; H Asahara; U S Jhala; B L Wagner; M Montminy
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

7.  Antagonism of endogenous growth hormone-releasing hormone (GHRH) leads to reduced proliferation and apoptosis in MDA231 breast cancer cells.

Authors:  Philip Zeitler; Gamini Siriwardana
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

8.  Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis.

Authors:  B E Wilson; E Mochon; L M Boxer
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

9.  An extranuclear locus of cAMP-dependent protein kinase action is necessary and sufficient for promotion of spiral ganglion neuronal survival by cAMP.

Authors:  Jinwoong Bok; Xiang-Ming Zha; Yang-Sun Cho; Steven H Green
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

10.  Targeted mutation of the CREB gene: compensation within the CREB/ATF family of transcription factors.

Authors:  E Hummler; T J Cole; J A Blendy; R Ganss; A Aguzzi; W Schmid; F Beermann; G Schütz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.